Screener
Cytek Biosciences, Inc. CTKB Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$12.16M-118% | -$18.87M-65.5% | -$44.08M— | -$5.48M-682% | -$5.58M+46.5% | ||
| $2.01M+6.3% | $1.87M-0.5% | $1.9M+2.3% | $1.92M+3.6% | $1.89M+4.5% | ||
| $5.34M-21.4% | $4.86M-26.7% | $5.53M-21.1% | $5.64M-20.1% | $6.79M-5.1% | ||
| —— | -$2.74M-2,089% | -$771K-139% | -$3.9M-129% | $0-100% | ||
| $2.22M+40.5% | $2.17M+155% | $1M+12.0% | $657K-35.0% | $1.58M+49.8% | ||
| —— | -$27.08M-386% | —— | $18.92M+220% | -$16.41M— | ||
| $0-100% | $0-100% | —— | —— | $4.51M+68.9% | ||
| $41K-97.0% | $5.07M+634% | $1.42M-49.2% | $2.09M+41,720% | $1.39M— | ||
| $1.61M+1,036% | $869K-42.8% | $2.94M+2,015% | $145K+3.6% | $142K+2.2% | ||
| —— | $3.98M+134% | -$1.23M+66.3% | —— | -$2.6M-52.1% | ||
| —— | -$25.19M-631% | -$2.43M+96.2% | —— | -$19.83M-326% | ||
| -$849K+42.2% | -$4.9M-403% | -$1.77M-261% | -$4.56M-137% | -$1.47M-129% |
FAQ
- What is Cytek Biosciences, Inc.'s free cash flow?
- After $6.0M of capital expenditures, Cytek Biosciences, Inc.'s free cash flow was -$12.1M over the trailing twelve months, down 211.1% year over year.
- Where does Cytek Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
